Analyst Downgrades – Hikma Pharmaceuticals Plc (OTC:HKMPF) Stock Gets Downgraded By Morgan Stanley from Overweight to Equal

Analyst Ratings For Hikma Pharmaceuticals Plc (OTC:HKMPF)

Story continues below

Today, Hikma Pharmaceuticals Plc (OTC:HKMPF) stock was downgraded by Morgan Stanley from Overweight to Equal.

There are 2 sell ratings, 1 hold rating on the stock.

The current consensus rating on Hikma Pharmaceuticals Plc (OTC:HKMPF) is Sell (Score: 1.33) with a consensus target price of per share, a potential .

Some recent analyst ratings include

  • 8/2/2017-Morgan Stanley was Downgraded by analysts at Morgan Stanley from a “Overweight ” rating to a ” Equal” rating.
  • 5/19/2017-Numis Securities Ltd Reiterated Rating of Buy .
  • 5/17/2017-Jefferies Group LLC was Downgraded by analysts at Jefferies Group LLC from a “Buy ” rating to a ” Underperform” rating.
  • 3/17/2017-HSBC Holdings plc was Downgraded by analysts at HSBC Holdings plc from a “Hold ” rating to a ” Reduce” rating.


    Recent Trading Activity for Hikma Pharmaceuticals Plc (OTC:HKMPF)
    Shares of Hikma Pharmaceuticals Plc closed the previous trading session at 18.60 up +0.20 1.09% with 100 shares trading hands.

    An ad to help with our costs